Khilola Shukurova’s Post

Insightful article from McKinsey & Company on upcoming #medtech trends in 2024. If you're light on time, read my key takeaways. ➡ Although 2023 was a quieter year for the industry, overall medtech revenue will be up on pre-pandemic levels ➡ The correlation between profit margin improvement and valuation has almost tripled since 2019 ➡ FDA approvals of AI and machine-learning-enabled medtech products reached an all-time high in 2023 ➡ China, Japan, and the United States will contribute two-thirds of near-term industry growth in medtech with a dampened outlook across Europe ➡ Medtech companies have $55 billion of cash and cash equivalents in "dry powder" from bumper profits during the pandemic Charlie Dell Nick Bellwood Gilbert Carrara, Jr. MD Stephen Irish Beryl Chu

📣 Great news! Medtech industry leaders have reason to be energized by the promise of 2024! In this article from McKinsey & Company, 200+ #Medtech executives have weighed in to provide #insights and seven #predictions about the evolving industry landscape in the coming year. "The new year will bring #innovations that improve more lives, opportunities to create #value, and fresh approaches that adapt to #market-shaping trends. Although obstacles remain, the #medtech industry is poised to continue to deliver benefits to all its #stakeholders." 1. Industry #growth will likely stabilize higher than the pre-pandemic average. 2. #investors will continue to seek profitable growth 3. The industry will deliver another banner year for #innovation 4. #performance across geographies will continue to be lumpy access to #technology and #training 5. Leaders in #ai adoption will start to see benefits of #scale 6. #mergersandacquisitions' deal volumes will likely remain stable, with a continued balance of growth and at-scale transactions 7. Penetration of #glp1 drugs will continue but is unlikely to have a meaningful impact on medtech growth

Ran across a recent article about key 2024 medtech trends. Biggest takeaway for me: this will be a banner year for medtech innovation. Patients are looking for better treatment options. Hospitals are looking for more efficient tech to uncover conditions. There is a lot of pressure for the industry to go-to-market, faster, with these new solutions. I am curious how these companies will enable their buyers to easily access these new products and services. The digital learning and digital buying experiences will have to be exceptional. Customers will change vendors if they can't buy new things confidently whenever and however they prefer. Agree/disagree? What are your biggest takeaways from the article? #medtech #meddevice #lifesciences

The Medtech Revolution in 2024: Get Ready for a Wave of Innovation! Over 200 visionary leaders shaped next year's predictions, with insights from McKinsey's latest report on the future of Medtech. Last year surprised with explosive growth, record product approvals, and strategic restructurings that propelled business excellence. In 2024, the industry goes further: high expectations with stable growth, driven by disruptive technologies and demographic shifts dictating a new era of prosperity. Profit-hungry investors see Medtech as a goldmine, with a growing focus on profitability and cash flow to reap the rewards of innovation. The stage is set for an innovation explosion, with cardiovascular, digital, and robotic health leading the way to a global wellness revolution. From China to the USA, the industry expands, driving global growth while challenging boundaries and shaping the future of healthcare. As artificial intelligence becomes ubiquitous, companies leading adoption reap the benefits of scalability, gearing up to dominate the market. Mergers and acquisitions continue to shape the Medtech landscape, with an exciting mix of growth transactions and large-scale opportunities. And despite the emergence of GLP-1 therapies, the industry remains resilient, with proactive narratives guiding the way to a new era of healthcare excellence. [2] [1] FDA Approvals, notably the European Market is moving slowly with the new MDR. Moreover, this increase in FDA approvals is a significant reflection of the escape from the European Market. Will there be shortages or new extensions and deadlines? Let's evaluate the scenes from the next chapters. [2] S&P Capital IQ, S&P Global Market Intelligence Source: https://www.mckinsey.com/ #medicaldevices #medicalinnovation #healthtech #medtech https://mck.co/3OxBntu

#worthsharing 1 min read: Delving into McKinsey's 2024 Medtech outlook unveils an industry at a pivotal crossroads, marked by a contrast of groundbreaking product approvals and strategic divestitures against a backdrop of profitability pressures and geographic disparities in performance. 🔍 Key Takeaways: 💡 Stabilizing Growth: Post-pandemic, Medtech is poised for stabilized growth, fueled by demographic changes and novel technologies. 💡Innovation Boom: Record FDA approvals signal a banner year for innovation, especially in AI, cardiovascular health, and digital healthcare devices. 💡Profitability Focus: Amidst investor scrutiny, companies are turning their lens towards profitability and cash flow as crucial value drivers. A standout example is the advent of GLP-1 drugs for weight loss, illustrating the intricate interplay between drug development and Medtech markets. This trend has influenced investor sentiment, as these drugs gain traction, there's been a noticeable shift in investment patterns, with a move away from obesity-related device stocks, highlighting the importance of Medtech companies adapting to both market demands and emerging healthcare solutions. As we look towards 2024, the Medtech industry stands at the precipice of transformative change, with innovation and strategic adaptation being key to navigating the evolving healthcare ecosystem. #Medtech2024 #HealthcareInnovation #StrategicGrowth #MedtechTrends #mckinseyinsights

Interesting insights happening in the 2024 MedTech Industry Landscape. This year promises innovation, value creation, and adaptability in the face of ever-changing market trends. Check it out here. #medtech #servicelogistics https://lnkd.in/g-28uYye

Curious what's on the horizon in MedTech? Stay curious but you can stop looking. After conversations with more than 200 executives, McKinsey lays out 7 predictions for the MedTech landscape this year. #Healthcare #Innovation #MedTech #Argano #Argano4Salesforce

Curious what's on the horizon in MedTech? Stay curious but you can stop looking. After conversations with more than 200 executives, McKinsey lays out 7 predictions for the MedTech landscape this year. #Healthcare #Innovation #MedTech

Curious what's on the horizon in MedTech? Stay curious but you can stop looking. After conversations with more than 200 executives, McKinsey lays out 7 predictions for the MedTech landscape this year. #Healthcare #Innovation #MedTech

What can we expect from medtech in 2024?   My colleagues spoke with more than 200 industry leaders and drew insights from McKinsey’s latest decade-ahead medtech report to offer seven predictions about the evolving industry landscape in the coming year.   In a new article, we reflect on the past year’s growth and challenges, and share why industry leaders have reason to be energized by the promise of 2024   #medtech #lifesciences #healthcare #meddevice #medtechinnovation